VCP-activating compounds improved TDP-43 aggregate clearance in laboratory cell models
Original source
Novel VCP activator reverses multisystem proteinopathy nuclear proteostasis defects and enhances TDP-43 aggregate clearance. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Peer review
- Preprint, not yet peer reviewed
Related topics
Researchers identified four compounds that activate valosin-containing protein (VCP) and increased clearance of insoluble nuclear TDP-43 aggregates in cell models of multisystem proteinopathy. The work links disease-associated VCP variants with impaired nuclear protein handling, but it does not show a treatment benefit in people with ALS or multisystem proteinopathy.
Why this matters
The findings identify VCP activation as a possible route for future drug development in diseases involving VCP variants and TDP-43 accumulation. The work was done in cells, so it does not yet change treatment or establish that these compounds are safe or effective in people.
Limitations and context
This is preclinical laboratory research reported as a bioRxiv preprint and journal article. The reported results come from engineered cells and compound testing, not from patients or a clinical trial. Animal studies and human studies would still be needed to determine whether the compounds work safely in living organisms.